leisure time -WSS

leisure time

author：hotspot 2025-09-27 16:36:22 - browse：9214

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Statins may not be needed by millions of people, study suggests

Wikipedia

WSS

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Deposition: Sackler embraced plan to conceal OxyContin’s strength

New report analyzes digital physical therapy solutions' effectiveness

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

explore

Supreme Court strikes down use of affirmative action

Millions may soon lose Medicaid when they don't have to

The high cost of giving birth even with insurance

Patients, doctors are clashing about side effects of hormonal birth control

Apple is now the first public company to be valued at $3 trillion

How faith leaders like me can help address America's obesity epidemic

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Bright Health sells Medicare Advantage business to Molina

Statins may not be needed by millions of people, study suggests

hotspot

'Essentially witchcraft:' A former naturopath takes on the field

Biden administration plans revamp of organ transplant system

Sea level rise could wash away turtle breeding grounds around the world, researchers say

Study: Why relieving medical debt did not improve financial outcomes

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

The thinking behind the controversial eating disorder chatbot Tessa

Wikipedia

Wikipedia

focus

hotspot